Two decades of progress in glioma methylation research: the rise of temozolomide resistance and immunotherapy insights DOI Creative Commons
Xianhao Huo, Haoyuan Li,

Yixiang Xing

et al.

Frontiers in Neuroscience, Journal Year: 2024, Volume and Issue: 18

Published: Sept. 2, 2024

Aims This study aims to systematically analyze the global trends in glioma methylation research using bibliometric methodologies. We focus on identifying scholarly trajectory and key interests, we utilize these insights predict future directions within epigenetic context of glioma. Methods performed a comprehensive literature search Web Science Core Collection (WoSCC) identify articles related published from January 1, 2004, December 31, 2023. The analysis included full-text publications English language excluded non-research publications. Analysis visualization were GraphPad Prism, CiteSpace, VOSviewer software. Results identified 3,744 WoSCC database, including 3,124 original 620 review articles. output gradually increased 2004 2007, followed by significant increase after 2008, which peaked 2022. A minor decline publication was noted during 2020–2021, potentially linked coronavirus disease 2019 pandemic. United States China leading contributors, collectively accounting for 57.85% total output. Helmholtz Association Germany, German Cancer Research Center (DKFZ), Ruprecht Karls University Heidelberg most productive institutions. Journal Neuro-Oncology led terms volume, while had highest Impact Factor. publishing authors revealed Michael Weller as prolific contributor. co-citation network David N. Louis's article frequently cited. keyword “temozolomide,” “expression,” “survival,” “DNA methylation” prominent keywords, “heterogeneity,” “overall survival,” “tumor microenvironment” showed strongest citation bursts. Conclusions findings this illustrate increasing interest methylation, with notable over past two decades. provides overview landscape, highlighting importance temozolomide, DNA tumor microenvironment research. Despite its limitations, offers valuable into current potential directions, particularly realm immunotherapy editing techniques.

Language: Английский

Identification of TMZ resistance‐associated histone post‐translational modifications in glioblastoma using multi‐omics data DOI Creative Commons
Liguo Ye,

Lingui Gu,

Yaning Wang

et al.

CNS Neuroscience & Therapeutics, Journal Year: 2024, Volume and Issue: 30(3)

Published: March 1, 2024

Abstract Backgroud Glioblastoma multiforme (GBM) is among the most aggressive cancers, with current treatments limited in efficacy. A significant hurdle treatment of GBM resistance to chemotherapeutic agent temozolomide (TMZ). The methylation status MGMT promoter has been implicated as a critical biomarker response TMZ. Methods To explore mechanisms underlying resistance, we developed two TMZ‐resistant cell lines through gradual increase TMZ exposure. Transcriptome sequencing revealed that alterations histone post‐translational modifications might be instrumental conferring resistance. Subsequently, multi‐omics analysis suggests strong association between H3 lysine 9 acetylation (H3K9ac) levels and Results We observed correlation expression H3K9ac MGMT, particularly unmethylated samples. More importantly, our findings suggest may enhance transcription by facilitating recruitment SP1 factor binding site. Additionally, analyzing single‐cell transcriptomics data from matched primary recurrent tumors treated TMZ, modeled molecular shifts occurring upon tumor recurrence. also noted reduction stem characteristics, accompanied an H3K9ac, SP1, levels, underscoring potential role relapse following therapy. Conclusions appears its sites within locus, consequently upregulating driving GBM.

Language: Английский

Citations

6
Nanotechnology as a new strategy for the diagnosis and treatment of gliomas DOI Creative Commons
Jun Lei,

Yiyang Huang,

Yichuan Zhao

et al.

Journal of Cancer, Journal Year: 2024, Volume and Issue: 15(14), P. 4643 - 4655

Published: Jan. 1, 2024

Glioma is the most common malignant tumor of central nervous system (CNS), and characterized by high aggressiveness a recurrence rate.Currently, main treatments for gliomas include surgical resection, temozolomide chemotherapy radiotherapy.However, prognosis glioma patients after active standardized treatment still poor, especially glioblastoma (GBM); median survival only 14.6 months, 5-year rate 4-5%.The current challenges in difficulty complete poor blood-brain barrier (BBB) drug permeability, therapeutic resistance, tumor-specific targeting.In recent years, rapid development nanotechnology has provided new directions diagnosing treating gliomas.Nanoparticles (NPs) are excellent surface tunability, precise targeting, biocompatibility, safety.In addition, NPs can be used gene therapy, photodynamic antiangiogenic therapy combined with biomaterials thermotherapy.In decades, breakthroughs have been made various functional NPs, expected to become strategy diagnosis treatment.In this paper, we review obstacles discuss potential latest glioma.

Language: Английский

Citations

4
The epigenetic mechanisms involved in the treatment resistance of glioblastoma DOI Open Access

Aanya Shahani,

Hasan Slika, Ahmed Elbeltagy

et al.

Cancer Drug Resistance, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 25, 2025

Glioblastoma (GBM) is an aggressive malignant brain tumor with almost inevitable recurrence despite multimodal management surgical resection and radio-chemotherapy. While several genetic, proteomic, cellular, anatomic factors interplay to drive promote treatment resistance, the epigenetic component remains among most versatile heterogeneous of these factors. Herein, landscape GBM refers a myriad modifications processes that can alter gene expression without altering genetic code cancer cells. These encompass DNA methylation, histone modification, chromatin remodeling, non-coding RNA molecules, all which have been found be implicated in augmenting tumor’s behavior driving its resistance therapeutics. This review aims delve into underlying interactions mediate this role for each components. Further, it discusses two-way relationship between heterogeneity plasticity, are crucial effectively treat GBM. Finally, we build on previous characterization explore specific targets investigated development promising therapeutic agents.

Language: Английский

Citations

0
Towards Effective Treatment of Glioblastoma: The Role of Combination Therapies and the Potential of Phytotherapy and Micotherapy DOI Creative Commons
Ludovica Gaiaschi, Maria Grazia Bottone, Fabrizio De Luca

et al.

Current Issues in Molecular Biology, Journal Year: 2024, Volume and Issue: 46(12), P. 14324 - 14350

Published: Dec. 19, 2024

Glioblastoma multiforme (GBM) is one of the most aggressive and difficult-to-treat brain tumors, with a poor prognosis due to its high resistance conventional therapies. Current treatment options, including surgical resection, radiotherapy, chemotherapy, have limited effectiveness in improving long-term survival. Despite emergence new therapies, monotherapy approaches not shown significant improvements, highlighting need for innovative therapeutic strategies. Combination therapies appear be promising solution, as they target multiple molecular pathways involved GBM progression. One area growing interest incorporation phytotherapy micotherapy complementary treatments, which offer potential benefits their anti-tumor, anti-inflammatory, immunomodulatory properties. This review examines current challenges treatment, discusses combination highlights role integrative options management.

Language: Английский

Citations

2
Histone-acetyl epigenome regulates TGF-β pathway-associated chemoresistance in colorectal cancer DOI Creative Commons
Xianglong Tian, Guihua Liu, Linhua Ji

et al.

Translational Oncology, Journal Year: 2024, Volume and Issue: 51, P. 102166 - 102166

Published: Nov. 9, 2024

Language: Английский

Citations

1
Two decades of progress in glioma methylation research: the rise of temozolomide resistance and immunotherapy insights DOI Creative Commons
Xianhao Huo, Haoyuan Li,

Yixiang Xing

et al.

Frontiers in Neuroscience, Journal Year: 2024, Volume and Issue: 18

Published: Sept. 2, 2024

Aims This study aims to systematically analyze the global trends in glioma methylation research using bibliometric methodologies. We focus on identifying scholarly trajectory and key interests, we utilize these insights predict future directions within epigenetic context of glioma. Methods performed a comprehensive literature search Web Science Core Collection (WoSCC) identify articles related published from January 1, 2004, December 31, 2023. The analysis included full-text publications English language excluded non-research publications. Analysis visualization were GraphPad Prism, CiteSpace, VOSviewer software. Results identified 3,744 WoSCC database, including 3,124 original 620 review articles. output gradually increased 2004 2007, followed by significant increase after 2008, which peaked 2022. A minor decline publication was noted during 2020–2021, potentially linked coronavirus disease 2019 pandemic. United States China leading contributors, collectively accounting for 57.85% total output. Helmholtz Association Germany, German Cancer Research Center (DKFZ), Ruprecht Karls University Heidelberg most productive institutions. Journal Neuro-Oncology led terms volume, while had highest Impact Factor. publishing authors revealed Michael Weller as prolific contributor. co-citation network David N. Louis's article frequently cited. keyword “temozolomide,” “expression,” “survival,” “DNA methylation” prominent keywords, “heterogeneity,” “overall survival,” “tumor microenvironment” showed strongest citation bursts. Conclusions findings this illustrate increasing interest methylation, with notable over past two decades. provides overview landscape, highlighting importance temozolomide, DNA tumor microenvironment research. Despite its limitations, offers valuable into current potential directions, particularly realm immunotherapy editing techniques.

Language: Английский

Citations

0